Business Context and Reporting Period
This Form 8-K filing by Illumina, Inc. was submitted on January 12, 2015, reporting preliminary results presented at the J.P. Morgan Healthcare Conference. The filing covers the fourth quarter ended December 28, 2014, and provides forward-looking guidance for the fiscal year 2015.
Key Financial Metrics
- Q4 2014 Revenue: $512 million (preliminary, subject to audit).
- Q4 2014 Non-GAAP EPS: Slightly above the top end of the guidance range (specific value not disclosed).
- FY 2015 Revenue Growth Outlook: Approximately 20%.
- FY 2015 Non-GAAP Diluted EPS: $3.12 to $3.18.
- FY 2015 GAAP Diluted EPS: $2.73 to $2.79.
- FY 2015 Non-GAAP Gross Margin: Approximately 73%.
- FY 2015 Pro Forma Tax Rate: Approximately 28%.
- Weighted Average Diluted Shares (FY 2015): Approximately 150 million.
Material Changes and Adjustments
The filing details specific adjustments reconciling Non-GAAP to GAAP earnings for the 2015 outlook:
- Amortization of acquired intangible assets: $(0.21) per share.
- Non-cash interest expense: $(0.17) per share (related to convertible debt instruments).
- Headquarter relocation: $(0.01) per share (accretion of interest expense on lease exit liability).
Guidance, Outlook, and Risks
Management projects approximately 20% revenue growth for fiscal year 2015. The guidance assumes a full-year non-GAAP gross margin of roughly 73% and a pro forma tax rate of 28%. The company explicitly states that actual results could differ materially from these projections due to risks and uncertainties. Full quarterly results for Q4 and FY 2014 will be announced during the upcoming earnings call. The information provided is preliminary and subject to audit.
Investor Verification Checklist
- Verify the final audited Q4 2014 revenue and EPS figures once the official earnings call is held.
- Confirm the specific Q4 2014 guidance range to validate the claim that results were "slightly above the top end."
- Review the upcoming Form 10-K for the fiscal year ended December 28, 2014, for detailed risk factors and full financial statements.
- Monitor the impact of the headquarter relocation and convertible debt interest on future cash flows.